Table 2.
Clinical Characteristics of the Study Population
| Overall | White patients | Black patients | P value (white patients vs black patients) | |
|---|---|---|---|---|
| n | 304 | 167 | 137 | |
| Male sex, n (%) | 198 (65) | 111 (67) | 87 (64) | .5896 |
| Age (y) | 48.5 (44–53) | 48 (43–52) | 49 (46–53) | .1242 |
| Baseline weight (kg) | 85 (75–98) | 83 (73–95) | 89 (79–102) | .0009 |
| Body mass index (kg/m2) | 28.4 (25.2–32.6) | 27.6 (24.5–31.6) | 28.8 (26.6–34.2) | .0013 |
| Hb (g/dL) | 15.1 (14.2–15.9) | 15.4 (14.5–16.1) | 14.8 (13.8–15.5) | 2.9 × 10−5 |
| Serum creatinine (mg/dL) | 0.9 (0.8–1.0) | 0.9 (0.8–1.0) | 1.0 (0.8–1.1) | .0003 |
| Alanine aminotransferase (IU/mL) | 66 (46–105) | 74 (52–139) | 59.5 (41–83) | 6.2 × 10−5 |
| HCV RNA level (log10IU/mL) | 6.5 (5.7–6.8) | 6.5 (5.6–6.8) | 6.4 (5.7–6.7) | .2973 |
| METAVIR activity, n (%) | ||||
| A1 | 61 (20) | 36 (22) | 25 (18) | .7578 |
| A2 | 83 (27) | 44 (26) | 39 (28) | |
| A3 | 160 (53) | 87 (52) | 73 (53) | |
| METAVIR fibrosis, n (%) | ||||
| F0–2 | 250 (82) | 137 (82) | 113 (82) | .9194 |
| F3–4 | 54 (18) | 30 (18) | 24 (18) |
NOTE. Values are expressed as median (25th to 75th percentiles) unless otherwise specified.